Attenuation of skeletal muscle atrophy via protease inhibition

Journal of Applied Physiology

Volumn 99, Issue 5, 2005, Pages 1719-1727

  Morris, Carl A ^a   Morris, Linda D ^a   Kennedy, Ann R ^a   Sweeney, H Lee ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bowman Birk inhibitor; Hindlimb unloading; Protease inhibitors; Protein degradation

Indexed keywords

BOWMAN BIRK INHIBITOR; PROTEINASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

AGE DISTRIBUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CACHEXIA; CELL SIZE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; ENZYME INHIBITION; HINDLIMB; IMMOBILIZATION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINASE INHIBITION; SEPSIS; SKELETAL MUSCLE; WEIGHTLESSNESS;

ANIMALS; BODY WEIGHT; CELL SIZE; DESMIN; HINDLIMB SUSPENSION; MALE; MICE; MICE, INBRED C57BL; MUSCLE CONTRACTION; MUSCLE FIBERS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; ORGAN SIZE; PEPTIDE HYDROLASES; SERINE PROTEINASE INHIBITORS; TALIN; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

EID: 27544510642     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.01419.2004     Document Type: Article

References (46)

1. Allen DL, Linderman JK, Roy RR, Bigbee AJ, Grindeland RE, Mukku V, and Edgerton VR. Apoptosis: a mechanism contributing to remodeling of skeletal muscle in response to hindlimb unweighting. Am J Physiol Cell Physiol 273: C579-C587, 1997.
2. Badalamente MA, Hurst LC, and Stracher A. Neuromuscular recovery using calcium protease inhibition after median nerve repair in primates. Proc Natl Acad Sci USA 86: 5983-5987, 1989.
3. Barton-Davis ER, Shoturma DI, Musaro A, and Rosenthal N. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 95: 15603-15607, 1998.
4. Bawadi HA, Antunes TM, Shih F, and Losso JN. In vitro inhibition of the activation of pro-matrix metalloproteinase 1 (Pro-MMP-1) and Pro-matrix metalloproteinase 9 (Pro-MMP-9) by rice and soybean Bowman-Birk inhibitors. J Agric Food Chem 52: 4730-4736, 2004.
5. Billings PC, St. Clair W, Maki PA, and Kennedy AR. Distribution of the Bowman Birk protease inhibitor in mice following oral consumption. Cancer Lett 62: 191-197, 1992.
6. Birk Y. The Bowman-Birk inhibitor. Im J Pept Protein Res 25: 113-131, 1985.
7. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, and Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001a.
8. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, and Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014-1019, 2001b.
9. Brooks SV and Faulkner JA. Contractile properties of skeletal muscles from young, adult and ages mice. J Physiol 404: 71-82, 1988.
10. Chen LY, Li P., He Q, Jiang LQ, Cui CJ, Xu L, and Liu LS. Transgenic study of chymase in heart remodeling. J Hypertens 20: 2047-2055, 2002.
11. Criswell DS, Booth FW, DeMayo F, Schwartz RJ, Gordon SE, and Fiorotto ML. Overexpression of IGF-I in skeletal muscle of transgenic mice does not prevent unloading-induced atrophy. Am J Physiol Endocrinol Metab 275: E373-E379, 1998.
12. Dalhmann B, Kuehn L, and Reinauer H. Susceptibility of muscle soluble proteins to degradation by mast cell chymase. Biochim Biophys Acta 761: 23-33, 1983.
13. Du J, Wang X, Miereies C, Bailey J, Debigare R, Zheng B, Price S, and Mitch W. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113: 115-123, 2004.
14. Goldberg AL. Protein turnover in skeletal muscle. II. Effects of denervation and cortisone on protein catabolism in skeletal muscle. J Biol Chem 244: 3223-3229, 1969.
15. Heath R, Kay J, Kuehn L, Dalhmann B, Stauber WT, and Mayer M. Immunochemical characterization of the myofibrillar proteinase from cultured rat myocytes as chymase. Biochem J 14: 675-683, 1987.
16. Hori S, Yamada M, Ohtani S, Hori C, Yokomizo T, Webb T, and Shimokawa T. Myonase is localized in skeletal muscle myofibrils. J Biochem (Tokyo) 132: 417-425, 2002.
17. Hornberger TA, Hunter RB, Kandarian SC, and Esser KA. Regulation of translation factors during hindlimb unloading and denervation of skeletal muscle in rats. Am J Physiol Cell Physiol 281: C179-C187, 2001.
18. Hunter RB and Kandarian SC. Disruption of either Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 114: 1504-1511, 2004.
19. Ikemoto M, Nikawa T, Takeda S, Watanabe C, Kitano T, Baldwin KM, Izumi R, Nonaka I, Towatari T, Teshima S, Rokutan K, and Kishi K. Space shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association with activation of ubiquitin-proteasome pathway. FASEB J 15: 1279-1281, 2001.
20. Jaspers SR and Tischler ME. Atrophy and growth failure of rat hindlimb muscles in tail-cast suspension. J Appl Physiol 57: 1472-1479, 1984.
21. Kassell B. Trypsin and chmyotrypsin inhibitors from soybeans. Methods Enzymol 19: 853-862, 1970.
22. Kennedy AR. Chemopreventive agents: protease inhibitors. Pharmacol Ther 78: 167-209, 1998.
23. Kennedy AR. Overview: anticarcinogenic activity of protease inhibitors. In: Protease Inhibitors as Cancer Chemopreventive Agents, edited by Troll W and Kennedy AR. New York: Plenum, 1993, p. 9-64.
24. Kennedy AR, Billings PC, Maki PA, and Newberne P. Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA. Nutr Cancer 19: 191-200, 1993.
25. Kennedy AR, Szuhaj BF, Newberne PM, and Billings PC. Preparation and production of a cancer Chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 19: 281-302, 1993.
26. Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fournier JG, Verdiere-Sahuque M, Fardeau M, and Alameddine HS. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol 205: 158-170, 1999.
27. Larionova NI, Gladysheva IP, Tikhonova TV, and Kazanskaya NF. Inhibition of cathepsin G and human granulocyte elastase by multiple forms of Bowman-Birk type soybean inhibitor (translated from Russian). Biokhimiia 58: 1437-1444, 1993.
28. Leskinen MJ, Lindstedt KA, Wang Y, and Kovanen PT. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol 23: 238-243, 2003.
29. Linderman JK, Gosselink KL, Booth FW, Mukku V, and Grindeland RE. Resistance exercise and growth hormone as countermeasures for skeletal muscle atrophy in hindlimb-suspended rats. Am J Physiol Regul Integr Comp Physiol 267: R365-R371, 1994.
30. Loughna P, Goldspink G, and Goldspink DF. Effect of inactivity and passive stretch on protein turnover in phasic and postural rat muscles. J Appl Physiol 61: 173-179, 1986.
31. Manzone H, Billings PC, Cummings WN, Feldman R, Clark LC, Odell CS, Koran AM, Atiba JO, Meyskens FL, and Kennedy AR. Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. Cancer Epidemiol Biomarkers Prev 4: 521-527, 1995.
32. Mitchell PO and Pavlath GK. A muscle precursor cell-dependent pathway contributes to muscle growth after atrophy. Am J Physiol Cell Physiol 281: C1706-C1715, 2001.
33. Morey ER. Spaceflight and bone turnover: correlation of a new rat model of weightlessness. Bioscience 29: 168-172, 1979.
34. Oreffo VIC, Billings PC, Kennedy AR, and Witschi H. Acute effects of the Bowman-Birk protease inhibitor in mice. Toxicology 69: 165-176, 1991.
35. Resnick A, Menashe O, Bar-Shai M, Coleman R, and Carmeli E. Expression of matrix metalloproteinases, inhibitor, and acid phosphatase in muscles of immobilized hindlimbs of rats. Muscle Nerve 27: 51-59, 2003.
36. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, and Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412, 2004.
37. Sangorrin MP, Marione CB, and Sanchez JJ. Myofibril-bound serine protease and its endogenous inhibitor in mouse: extraction, partial characterization and effect on myofibrils. Comp Biochem Physiol B Biochem Mol Biol 131: 713-723, 2002.
38. Solomon V and Goldberg AL. Importance of the ATP-ubiquitin-proteosome pathway in the degradation of soluble and myofibrillar proteins in rabbit skeletal muscle extracts. J Biol Chem 271: 26690-26697, 1996.
39. Stevenson EJ, Giresi PG, Koncarevic A, and Kandarian SC. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol 551: 33-48, 2003.
40. Stitt T, Drujan D, Clarke B, Panaro F, Timofeyva Y, Kline W, Gonzalez M, Yancopoulos G, and Glass D. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395-403, 2004.
41. 2+-activated and ATP-ubiquitin-dependent proteinases in the unweighted rat soleus muscle. Biochem J 316: 65-72, 1996.
42. Tawa NE Jr, Odessey R, and Goldberg AL. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 100: 197-203, 1997.
43. Tidball JG and Spencer MJ. Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J Physiol 545: 819-828, 2002.
44. Ugai S, Tamura T, Tanahashi N, Takai S, Komi N, Chung CH, Tanaka K, and Ichihara A. Purification and characterization of the 26S proteasome complex catalyzing ATP-dependent breakdown of ubiquitin-ligated proteins from rat liver. J Biochem (Tokyo) 113: 754-768, 1993.
45. Wan XS, Meyskens FL, Armstrong WB, Taylor TH, and Kennedy AR. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk inhibitor. Cancer Epidemiol Biomarkers Prev 8: 601-608, 1999.
46. Ware JH, Wan XS, Rubin H, Schechter NM, and Kennedy AR. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344: 133-138, 1997.